business

The 2020 budget includes a 15 percent increase in public funding for research and development next year, but some scientists want more details on where the money will go.

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.

Wong Chi-huey, who was the president of Academia Sinica until 2016, was found not guilty of taking bribes from a pharmaceutical company.

LunaDNA receives Securities and Exchange Commission approval to treat the data as currency.

EncrypGen will enable individuals to sell their deidentified data for research.

Critics say the misleading term actually refers to a heterogeneous population of cells, including possible tissue-specific progenitor cells and nonstem cells all lumped together.

Silicon Valley’s early-stage funding model could address a dearth of opportunities for young investigators just launching new projects.

Computational biologists are optimistic that the purchase of the world’s largest hub for open-source computer code will not affect the way they use GitHub for science.

A security researcher found the email addresses and encrypted passwords of more than 92 million users of the genealogy site on a private server outside the company.

Almost half of all patents relating to the genes of marine organisms belong to one large international corporation, BASF, a new study reveals.  

Luna DNA, Nebula Genomics, and other “bio-brokers” will allow customers to make money by granting access to their genetic and personal information for research purposes.

The company raised more than $700 million based on false claims to investors, according to the complaint.

Biotech stocks fell in response to the news. 

With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.

The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

Their $1.5 billion bid, which topped Thermo Fisher Scientific’s $1.3 billion offer for the genetic analysis company, was rejected.